FDA sees no safety issues with Pfizer HIV drug

October 6, 2009

(AP) -- The Food and Drug Administration says an HIV drug from Pfizer appears safe for expanded use in patients who have not taken other drugs to combat the virus.

Selzentry is already approved as a secondary option for HIV patients who are not responding to other antiviral drugs. Now the company is asking the FDA to approve the drug as a first-choice treatment.

FDA scientists appeared to favor the new use in briefing documents posted online Tuesday.

One review says "no new safety signals were identified in association" with the drug.

On Thursday, the will ask a panel of outside experts to vote on Selzentry's safety and effectiveness. The agency usually follows the group's advice, though it is not required to do so.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA approves antiretroviral drug

Related Stories

FDA approves antiretroviral drug

August 7, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

FDA: New warning needed for Chantix

February 3, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

FDA weighs approval of psychiatric drugs for kids

June 5, 2009

(AP) -- Three blockbuster psychiatric drugs currently approved for adults also appear to work in adolescents, though federal health officials have concerns about exposing younger patients to the drugs' side effects.

FDA questions safety of Glaxo kidney cancer drug

October 1, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

FDA panel backs Schering-Plough cancer drug

October 5, 2009

(AP) -- Federal health advisers voted 6-4 on Monday that the potential benefits of a Schering-Plough drug outweigh its toxic risks as a treatment for late-stage skin cancer.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.